मूलभूत आँकड़े
| LEI | 549300CL6P01M68QJ404 |
| CIK | 1674930 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Fulgent Genetics, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 1, 2025 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 1, 2025 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| August 1, 2025 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation August 1, 2025 Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation August 1, 2025 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| August 1, 2025 |
Exhibit 99.1 Fulgent Reports Second Quarter 2025 Financial Results • Core Revenue of $81.7 million grows 16% year-over-year • Raising Full Year 2025 Core Revenue Guidance to $320 million • GAAP gross profit of $34.4 million, or GAAP gross margin of 42.1%; Non-GAAP gross profit of $36.2 million, or Non-GAAP gross margin of 44.2% • GAAP loss of $19.0 million, or ($0.62) per share, inclusive of a one |
|
| May 15, 2025 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| May 2, 2025 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 2, 2025 |
Amended and Restated Director Compensation Program Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract |
|
| May 2, 2025 |
Exhibit 99.1 Fulgent Reports First Quarter 2025 Financial Results • Core Revenue of $73.5 million grows 16% year-over-year • Reiterating Full Year 2025 Core Revenue Guidance of $310 million • Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share • Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable s |
|
| May 2, 2025 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation May 2, 2025 Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation May 2, 2025 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| May 2, 2025 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 28, 2025 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| February 28, 2025 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation February 28, 2025 Exhibit 99. |
|
| February 28, 2025 |
Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware Fulgent Australia Pty Ltd Australia |
|
| February 28, 2025 |
Description of the registrant’s securities. Exhibit 4.2 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Fulgent Genetics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwise requires, all reference |
|
| February 28, 2025 |
Exhibit 19.1 FULGENT GENETICS, INC. INSIDER TRADING POLICY Adopted: September 16, 2016 Last Revised and Approved: February 26, 2024 This Insider Trading Policy (“Policy”) provides guidelines concerning transactions in the securities of Fulgent Genetics, Inc. (“Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Compan |
|
| February 28, 2025 |
Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results • Full Year Total Revenue of $283.5 million • Full Year Core Revenue grows 7% year-over-year to $281.2 million • Ended 2024 with $828.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.87 EL MONTE, CA, February 28, 2025 — Fulgent Genetics, |
|
| January 8, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| November 8, 2024 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| November 8, 2024 |
Exhibit 99.1 Fulgent Reports Third Quarter 2024 Financial Results • Total Revenue of $71.7 million • Core Revenue grows 9% year-over-year to $71.7 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, CA, November 8, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company wit |
|
| November 8, 2024 |
f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| November 8, 2024 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation November 8, 2024 Exhibit 99. |
|
| November 5, 2024 |
FLGT / Fulgent Genetics, Inc. / Hsieh Ming - SC 13D/A Activist Investment SC 13D/A 1 sc13da-minghsieh11524.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4399 Santa Anita Avenue El Mont |
|
| August 2, 2024 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| August 2, 2024 |
Exhibit 99.1 Fulgent Reports Second Quarter 2024 Financial Results • Total Revenue of $71.0 million • Core Revenue grows 5% year-over-year to $70.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 EL MONTE, CA, August 2, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with |
|
| August 2, 2024 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation August 2, 2024 Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation August 2, 2024 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| May 16, 2024 |
Submission of Matters to a Vote of Security Holders ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| May 3, 2024 |
Exhibit 99.1 Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, CA, May 3, 2024 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business an |
|
| May 3, 2024 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation May 3, 2024 Exhibit 99. |
|
| May 3, 2024 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 28, 2024 |
Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| February 28, 2024 |
Founded in 2011 | Located in El Monte, CA | NASDAQ:FLGT Investor Presentation February 28, 2024 Exhibit 99. |
|
| February 28, 2024 |
Exhibit 10.41 Rule 10b5-1 Issuer Repurchase Plan This Rule 10b5-1 Issuer Repurchase Plan (this “Plan”) is entered into this 12th day of December, 2023 between Fulgent Genetics, Inc. (“Company”) and Piper Sandler & Co. (“Broker”). Recitals Whereas, Company desires to establish this Plan to systematically repurchase shares of its common stock, par value $0.0001 per share (the “Shares”) in accordance |
|
| February 28, 2024 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2024 |
Description of the registrant’s securities. Exhibit 4.2 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2023, Fulgent Genetics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwis |
|
| February 28, 2024 |
Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million • Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-over-year to $66.5 million • Ended 2023 with $847.7 million of cash, cash equivalents, and investments in marketable sec |
|
| February 7, 2024 |
3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com February 7, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Form 10 |
|
| January 9, 2024 |
3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com January 9, 2024 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed Fe |
|
| November 14, 2023 |
3580 Camel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com November 14, 2023 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tracey Houser Terence O’Brien Re: Fulgent Genetics, Inc. Form 10-K for Fiscal Year Ended December 31, 2022 Filed |
|
| November 3, 2023 |
Exhibit 99.1 Fulgent Reports Third Quarter 2023 Financial Results • Core Revenue of $66 million represents Growth of 17% Year-over-Year • Additional Reimbursement from COVID-19 Test Sales yields Revenue of $19 million, for Total Revenue of $85 million • Reiterates Full Year 2023 Core Revenue Guidance of $260 million EL MONTE, CA, November 3, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” |
|
| November 3, 2023 |
Amended and Restated Executive Officer Incentive Plan Exhibit 10.2 Fulgent Genetics, Inc. Amended and Restated Executive Officer Incentive Plan Effective October 30, 2023 Introduction The Amended and Restated Executive Officer Incentive Plan (the “Plan”) is an annual incentive compensation program designed to support the pay for performance philosophy of Fulgent Genetics, Inc. (“Company”) by rewarding members of the executive management team for thei |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| November 3, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| November 3, 2023 |
Amended and Restated Incentive Compensation Recoupment Policy Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED INCENTIVE COMPENSATION RECOUPMENT POLICY I. Introduction The Compensation Committee of the Board of Directors (the “Committee”) of Fulgent Genetics, Inc. (the “Company”) believes it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces th |
|
| November 3, 2023 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Investor Presentation November 3, 2023 Exhibit 99. |
|
| August 4, 2023 |
Amended and Restated Bylaws of the registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF FULGENT GENETICS, INC. a Delaware Corporation TABLE OF CONTENTS Page ARTICLE 1 OFFICES 1 Section 1.1 Registered Office. 1 Section 1.2 Other Offices. 1 ARTICLE 2 STOCKHOLDERS’ MEETINGS 1 Section 2.1 Place of Meetings. 1 Section 2.2 Annual Meetings. 2 Section 2.3 Special Meetings. 2 Section 2.4 Notice of Meetings. 2 Section 2.5 Quorum and Voting. 3 Section |
|
| August 4, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 4, 2023 |
Exhibit 99.1 Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, CA, August 4, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-establish |
|
| August 4, 2023 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Investor Presentation August 4, 2023 Exhibit 99. |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 18, 2023 |
Amended and Restated 2016 Omnibus Incentive Plan of the registrant Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the i |
|
| May 18, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| May 18, 2023 |
As filed with the Securities and Exchange Commission on May 18, 2023 As filed with the Securities and Exchange Commission on May 18, 2023 Registration No. |
|
| May 18, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulgent Genetics, Inc. |
|
| May 5, 2023 |
Amended and Restated Non-Employee Director Compensation Policy, dated as of February 23, 2023. Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract |
|
| May 5, 2023 |
Exhibit 99.1 Fulgent Reports First Quarter 2023 Financial Results • Total Revenue of $66.2 million • Record Core Revenue of $62.7 million, growth of 150% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $250 million EL MONTE, CA, May 5, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic bu |
|
| May 5, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 5, 2023 |
Executive Officer Incentive Plan Exhibit 10.3 Fulgent Genetics, Inc. Executive Officer Incentive Plan Effective January 1, 2023 Introduction The Executive Officer Incentive Plan (the “Plan”) is an annual incentive compensation program designed to support the pay for performance philosophy of Fulgent Genetics, Inc. (“Company”) by rewarding members of the executive management team for their contributions in the achievement of corpo |
|
| May 5, 2023 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Investor Presentation May 5, 2023 Exhibit 99. |
|
| April 3, 2023 |
DEFA14A 1 flgt2023defa14asuppl.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| February 28, 2023 |
Exhibit 10.50 SECOND AMENDMENT TO LEASE THIS Second Amendment to Lease (this “Amendment”) is entered into as of February 3, 2014 (the “Effective Date”), between LC MED PROPERTY TT, LLC , a Delaware limited liability company (“Landlord”), successor-in-interest to iStar CTL I, L.P. (“Original Landlord”), and MIRACA LIFE SCIENCES, INC., a Delaware corporation (“Tenant”), successor-in interest to Cari |
|
| February 28, 2023 |
Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia Inform Diagnostics, Inc Delaware Fulgent Pharma Holdings, Inc. Delaware |
|
| February 28, 2023 |
Commercial Lease Agreement by and between Inform Diagnostics and Crawford Street DE, LLC Exhibit 10.51 LEASE OF PREMISES AT 15-19 CRAWFORD STREET NEEDHAM, MASSACHUSETTS FROM CRAWFORD STREET DE, LLC TO MIRACA LIFE SCIENCES, INC. TABLE OF CONTENTS Page SUMMARY OF BASIC TERMS iii ARTICLE I 1 ARTICLE II 5 Section 2.1 Lease Of The Premises 5 Section 2.2 Common Rights 5 Section 2.3 Parking 5 Section 2.4 Lease Term 6 Section 2.5 Security Deposit 6 Section 2.6 Lease Amendment 8 Section 2.6 Ri |
|
| February 28, 2023 |
Exhibit 10.46 Rule 10b5-1 Issuer Repurchase Plan This Rule 10b5-1 Issuer Repurchase Plan (this “Plan”) is entered into this 15th day of December, 2022 between Fulgent Genetics, Inc. (“Company”) and Piper Sandler & Co. (“Broker”). Recitals Whereas, Company desires to establish this Plan to systematically repurchase shares of its common stock, par value $0.0001 per share (the “Shares”) in accordance |
|
| February 28, 2023 |
Description of the registrant’s securities. Exhibit 4.3 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Fulgent Genetics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwis |
|
| February 28, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Fulgent Genetics, Inc. |
|
| February 28, 2023 |
As filed with the Securities and Exchange Commission on February 28, 2023 S-8 1 flgts-82023.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporati |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| February 28, 2023 |
2022 Fulgent Pharma Holdings, Inc. Omnibus Incentive Plan Exhibit 10.52 FULGENT PHARMA HOLDINGS, INC. 2022 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply as used herein and in the individual Awa |
|
| February 28, 2023 |
EXHIBIT 10.49 FIRST AMENDMENT AND PARTIAL RESTATEMENT OF LEASE THIS First Amendment and Partial Restatement of Lease (this “Amendment”) is entered into as of December 30, 2013 (the “Effective Date”), between LC MED PROPERTY TT, LLC, a Delaware limited liability company (“Landlord”), successor-in-interest to iStar CTL I, L.P. (“Original Landlord”), and MIRACA LIFE SCIENCES, INC., a Delaware corpora |
|
| February 28, 2023 |
Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results • Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million • Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million TEMPLE CITY, CA, February 28, 2023 — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company” |
|
| February 28, 2023 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Investor Presentation February 28, 2023 Exhibit 99. |
|
| February 28, 2023 |
Exhibit 10.48 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this "Second Amendment") dated and effective for reference purposes as of July 1, 2020, is made by and between WPT LAND 2 LP, a Delaware limited partnership ("Landlord), and INFORM DIAGNOSTICS, INC., a Delaware corporation ("Tenant). BACKGROUND: A. Landlord (as successor in interest to Liberty Property Limi |
|
| February 28, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| January 12, 2023 |
Commercial Lease Addendum (II) by and between Fulgent Therapeutics LLC and E&E Plaza LLC Exhibit 1.1 COMMERCIAL LEASE ADDENDUM (II) This LEASE ADDENDUM II to the Commercial Lease Agreement signed on February 1, 2018 by E&E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as describe below: 1. The Lessor agrees to extend this lease for ONE (1) year, starting on February 1, 2023 and expiring on January 31, 2024. 2. For t |
|
| January 12, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 3, 2023 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 3, 2023 |
Fulgent Expands Board of Directors with Addition of Reggie Groves Exhibit 99.1 Fulgent Expands Board of Directors with Addition of Reggie Groves TEMPLE CITY, California –January 3, 2023 – Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023. “Reggie possesses a diverse business skill set and a global perspective that we believe wil |
|
| November 23, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2022 (November 18, 2022) FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorpo |
|
| November 10, 2022 |
Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. |
|
| November 10, 2022 |
FLGT / Fulgent Genetics Inc / Hsieh Ming - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, A |
|
| November 7, 2022 |
Exhibit 10.2 FULGENT PHARMA HOLDINGS, INC. 2022 OMNIBUS INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD You (the “Grantee”) have been granted an award of Restricted Stock Units (the “Award”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Fulgent Pharma Holdings, Inc. 2022 Omnibus Incentive Plan, as amended from time to time (the “Plan”) |
|
| November 7, 2022 |
Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 —Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rar |
|
| November 7, 2022 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Investor Presentation November 7, 2022 Exhibit 99. |
|
| November 7, 2022 |
Amended and Restated Non-Employee Director Compensation Policy, dated as of August 1, 2022. Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract |
|
| November 7, 2022 |
Exhibit 99.2 Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company Fulgent Genetics aims to transform from a genomic diagnostic business into a fully integrated precision medicine company focused on oncology Fulgent Pharma’s proprietary novel nano-drug delivery technology platform synergistically underpins the combined businesses, potentially provi |
|
| November 7, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| November 7, 2022 |
Exhibit 10.3 AGREEMENT AND PLAN OF Merger BY AND AMONG FULGENT GENETICS, INC., FG MERGER SUB, inc., FULGENT PHARMA HOLDINGS, INC., AND THE STOCKHOLDERS SET FORTH HEREIN NOVEMBER 7, 2022 TABLE OF CONTENTS Page Article I THE MERGER 1 1.1 Merger 1 1.2 Effective Time 2 1.3 Effects of the Merger 2 1.4 Closing 2 1.5 Closing Deliverables. 2 1.6 Certificate of Incorporation and Bylaws 3 1.7 Directors and |
|
| November 7, 2022 |
Ming Hsieh Chairman, CEO, Founder Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT Announces Third Quarter 2022 Earnings and Acquisition of Fulgent Pharma November 7, 2022 Exhibit 99. |
|
| November 4, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| September 29, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| August 4, 2022 |
Exhibit 99.1 Fulgent Genetics Reports Second Quarter 2022 Financial Results ? Revenue totals $125.3 million ? Core Revenue grows 102% year-over-year to $45.3 million ? Raises full year core revenue outlook to $185 million from previously announced $180 million TEMPLE CITY, CA, August 4, 2022 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics?, ?Fulgent?, or the ?Company?), a technology-base |
|
| August 4, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| August 4, 2022 |
Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| June 30, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| May 19, 2022 |
Submission of Matters to a Vote of Security Holders ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 5, 2022 |
Press Release Announcing Appointment Jian Xie Exhibit 99.1 Fulgent Genetics Announces Promotions and Leadership Updates TEMPLE CITY, CA, May 3, 2022 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics?, ?Fulgent?, or the ?Company?), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a number of promotions and appointments acr |
|
| May 3, 2022 |
Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| May 3, 2022 |
Exhibit 99.1 Fulgent Genetics Reports First Quarter 2022 Financial Results ? Revenue totals $320.3 million ? Core Revenue excluding COVID-19 NGS testing grows 59% year-over-year to $25.1 million ? Raises full year revenue outlook to $660 million from previously announced $600 million ? Raises full year core revenue outlook to $180 million from previously announced $175 million TEMPLE CITY, CA, May |
|
| May 3, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 26, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets ! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 26, 2022 |
EX-2.1 2 flgt-ex217.htm EX-2.1 Exhibit 2.1 STRICTLY CONFIDENTIAL AGREEMENT AND PLAN OF Merger BY AND AMONG FULGENT THERAPEUTICS LLC, DUCKS ACQUISITION SUB, INC., FULGENT GENETICS, INC., SYMPHONY BUYER, INC., SOLELY IN ITS CAPACITY AS THE Stockholder Representative, Avista Capital Partners IV GP, L.P., AND, SOLELY FOR PURPOSES OF SECTION 6.21, ARTICLE VIII AND SECTION 10.14, THOSE COMPANY STOCKHOLD |
|
| April 18, 2022 |
Exhibit 99.1 Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results Proposed acquisition will add diagnostic offerings, including hematopathology and anatomic pathology, while also providing a highly complementary nationwide commercial infrastructure to support Fulgent?s rapidly expanding genomic testing footprint Preliminary first quarter reve |
|
| April 18, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 29, 2022 |
Fulgent Genetics, Inc. Incentive Compensation Recoupment Policy. EX-10.1 2 flgt-ex1017.htm EX-10.1 Exhibit 10.1 FULGENT GENETICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY Fulgent Genetics, Inc. has adopted this Incentive Compensation Recoupment Policy, which is effective as of March 28, 2022 (the “Effective Date”). 1.Certain Definitions. (a)“Board” means the Board of Directors of the Company. (b)“Committee” means the Compensation Committee of the Board. (c |
|
| March 29, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 29, 2022 |
DEF 14A 1 flgt-def14a20220518.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| February 28, 2022 |
Exhibit 10.41 AMENDED AND RESTATED LEASE by and between STORE MASTER FUNDING IX, LLC as Landlord and CYTOMETRY SPECIALISTS, INC., as Tenant. May 6, 2016 4823-7309-7009.2 STORE / CSI Labs Amended and Restated Lease Agreement 2580 Westside Dr., Alpharetta, GA File No.: 7210/02-432.1 TABLE OF CONTENTS ARTICLE/SECTION PAGE NO. Article I LEASE OF PREMISES; POSSESSION 1 Section 1.1. Lease to Tenant 1 Se |
|
| February 28, 2022 |
Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Cytometry Specialists, Inc. Georgia |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K closed UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT |
|
| February 23, 2022 |
Exhibit 99.1 Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results ? Full Year 2021 Total Revenue grows 135% year-over-year to $992.6 million; Q4 Revenue totals $251.7 million ? Full Year 2021 Core Revenue grows 236% year-over-year to $122.6 million; Q4 Core Revenue grows 234% year-over-year to $40.1 million TEMPLE CITY, CA, February 23, 2022 ?Fulgent Genetics, Inc. (NASDAQ: |
|
| February 23, 2022 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| February 23, 2022 |
1 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. |
|
| November 9, 2021 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| November 9, 2021 |
Exhibit 99.1 Fulgent Genetics Reports Third Quarter Financial Results ? Revenue grows 124% year-over-year to $227.9 million ? Core Revenue grows 292% year-over-year to $40.1 million ? Raises Full Year Revenue guidance to $930 million from $800 million, given recent strength in core and COVID-19 business TEMPLE CITY, CA, November 9, 2021 ?Fulgent Genetics, Inc. (NASDAQ: FLGT) (?Fulgent Genetics? or |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| November 9, 2021 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT 1 Exhibit 99.2 November 2021 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the ?Company?) about future events based on current views and assum |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q f UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| August 10, 2021 |
Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd. Exhibit 10.1 Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd This Restructuring Agreement of Fujian Fu |
|
| August 9, 2021 |
! UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 9, 2021 |
Exhibit 99.1 Fulgent Genetics Reports Second Quarter Financial Results ? Revenue grows 790% year over year to $153.6 million ? Core Revenue grows 296% year over year to $25.7 million ? Announces acquisition of CSI Laboratories ? Announces commercial agreement with Helio Health through strategic investment ? Announces incremental controlling investment in Chinese Joint Venture entity, FF Gene Biote |
|
| August 9, 2021 |
Founded in 2011 | Located in Los Angeles, CA | NASDAQ:FLGT 1 Exhibit 99.2 Disclaimer Forward-Looking Statements and Market Data This presentation contains forward-looking statements, which are statements other than those of historical facts and which represent the estimates and expectations of Fulgent Genetics, Inc. (the ?Company?) about future events based on current views and assumptions. Exampl |
|
| May 20, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 7, 2021 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION PROGRAM This Amended and Restated Director Compensation Program (this ?Program?) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the ?Company?), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 6, 2021 |
Exhibit 99.1 Fulgent Genetics Reports Record First Quarter Financial Results First Quarter 2021 Results: ? Record Revenue of $359.4 million, growing more than 4,500% year-over-year ? Record Billable tests delivered approximately 3.8 million, or 290 times the volume of first quarter of 2020 ? Gross Margin improved approximately 32 percentage points year-over-year ? NGS Revenue grew 115% year-over-y |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Defin |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| March 8, 2021 |
Exhibit 10.34 SUBLEASE AGREEMENT This SUBLEASE AGREEMENT (this ?Sublease?) is entered into as of July 1st, 2020 (the ?Effective Date?), between Medscan Laboratory (?Tenant?) and Fulgent Genetics (?Subtenant?), with reference to the following: A.Ten Voss, LTD, a Texas Limited Partnership, (?Landlord?) as Landlord, and Tenant with respect to that certain Lease Agreement dated June 17th, 2020 (the ?O |
|
| March 8, 2021 |
Exhibit 10.37 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the ?Company?), Fulgent Genetics, Inc., a Delaware corporation (?HoldCo?) and Jian Xie (?Executive?). 1. POSITION AND RESPONSIBILITIES (a) Position. Executive is employed by the Company to render services to the Compa |
|
| March 8, 2021 |
Exhibit 10.36 COMMERCIAL LEASE ADDENDUM #1 This is addendum to the Commercial Lease Agreement signed on February 1, 2018 by E & E Plaza LLC ("Lessor") and Fulgent Therapeutics LLC ("Lessee"). This document modifies the Commercial Lease Agreement as described below. 1. The Lessor agrees to extend this lease for Two (2) Years, starting on February 1, 2021 and expiring on January 31, 2023. 2. For thi |
|
| March 8, 2021 |
Exhibit 10.38 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT (the ?Agreement?), dated March 8, 2021, is by and among Fulgent Therapeutics LLC, a California limited liability company (the ?Company?), Fulgent Genetics, Inc., a Delaware corporation (?HoldCo?) and Jian Xie (?Executive?). WHEREAS, Executive is employed by the Company to render services to the Company in the position of Chief Operating Of |
|
| March 8, 2021 |
Exhibit 10.35 LEASE ASSIGNMENT & ASSUMPTION WHEREAS, by Service Center Lease Agreement (the "Lease") dated June 17, 2020, TEN-VOSS, LTD, "Landlord" or ?Lessor?, leased MEDSCAN LABORATORIES INC. hereinafter ?Tenant? or ?Lessee?, those certain premises at 8560 Katy Freeway, Suite 200, Houston, Texas 77024. WHEREAS, the Lease Term commenced September 1, 2020 and expires November 30, 2023 in accordanc |
|
| March 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 4, 2021 |
EX-99.1 2 flgt-ex9916.htm EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results Fourth Quarter 2020 Results: • Record Revenue of $295.0 million, growing more than 3,400% year-over-year • Record Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019 • Gross Margin improved over 8 percentage |
|
| February 5, 2021 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| December 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, Add |
|
| December 22, 2020 |
Joint Filing Agreement, dated as of December 22, 2020, by and among Mr. Hsieh and the Trust Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. |
|
| November 23, 2020 |
Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million Exhibit 99.1 Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million TEMPLE CITY, California – November 23, 2020 – Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020 |
|
| November 23, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 flgt-8k20201123.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of |
|
| November 20, 2020 |
Exhibit 1.1 FULGENT GENETICS, INC. EQUITY DISTRIBUTION AGREEMENT November 20, 2020 PIPER SANDLER & CO. BTIG, LLC OPPENHEIMER & CO. INC. c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o BTIG, LLC 65 East 55th Street New York, NY 10022 c/o Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, NY 10004 Ladies and Gentlemen: As further set forth in |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commissio |
|
| November 20, 2020 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-239964 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) $175,000,000 Common Stock We have entered into an equity distribution agreement, dated November 20, 2020, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, BTIG, LLC, or BTIG, and Oppenheimer & Co. Inc., or Oppenheimer, and collectively with Piper |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 9, 2020 |
Exhibit 99.1 Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million Third Quarter 2020 Results: • Record Revenue of $101.7 million, growing more than 880% year-over-year • Record Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-year • Gross Margin improved approximately 19 percentage poi |
|
| November 9, 2020 |
10-Q 1 flgt-10q20200930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| November 9, 2020 |
Exhibit 10.2 AIRCRAFT PURCHASE AGREEMENT between ServiceMaster Acceptance Corporation as Seller, and Fulgent Genetics, Inc. as Purchaser, involving that certain Cessna Aircraft Company, model 680 aircraft, bearing manufacturer Serial Number 680-0255 and United States Registration Number N860SM AIRCRAFT PURCHASE AGREEMENT This AIRCRAFT PURCHASE AGREEMENT dated as of August 18, 2020 (this “Agreement |
|
| October 21, 2020 |
Agreement for Purchase and Sale of Property, dated July 23, 2020 EX-2.1 2 flgt-ex216.htm EX-2.1 Exhibit 2.1 AGREEMENT FOR PURCHASE AND SALE OF PROPERTY and JOINT ESCROW INSTRUCTIONS By and Between 4401 Santa Anita Corporation, a California corporation, as Seller And Fulgent Genetics, Inc., a Delaware Corporation, as Buyer AGREEMENT FOR PURCHASE AND SALE OF REAL PROPERTY AND JOINT ESCROW INSTRUCTIONS THIS AGREEMENT FOR PURCHASE AND SALE OF REAL PROPERTY AND JOIN |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| September 25, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 flgt-8k20200924.htm 8-K FOR 2020 ATM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or oth |
|
| September 25, 2020 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-239964 PROSPECTUS SUPPLEMENT (to Prospectus dated August 12, 2020) $125,000,000 Common Stock We have entered into an equity distribution agreement, dated September 24, 2020, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, relating to shares of our common stock, par value $0.0001 per |
|
| September 25, 2020 |
EX-1.1 2 flgt-ex116.htm EX-1.1 Exhibit 1.1 FULGENT GENETICS, INC. EQUITY DISTRIBUTION AGREEMENT September 24, 2020 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Fulgent Genetics, Inc., a company organized under the laws of the State of Delaware (the “Company”), proposes to issu |
|
| September 22, 2020 |
As filed with the Securities and Exchange Commission on September 22, 2020 Registration No. |
|
| September 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| September 18, 2020 |
Fulgent Genetics, Inc. Amended and Restated 2016 Omnibus Incentive Plan EX-10.1 2 flgt-ex1016.htm EX-10.1 Exhibit 10.1 FULGENT GENETICS, INC. AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall |
|
| September 17, 2020 |
FLGT / Fulgent Genetics, Inc. / Gao Hanlin - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Han Lin Gao c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue Temple City, California 91780 (626) 350-0537 (Name, Ad |
|
| August 31, 2020 |
DEF 14A 1 flgt-def14a20200917.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| August 21, 2020 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2020 |
CORRESP 1 filename1.htm FULGENT GENETICS, iNC. 4978 Santa Anita Avenue Temple City, CA 91780 August 7, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor RE: Fulgent Genetics, Inc. Registration Statement on Form S-3 Filed July 21, 2020, as amended on August 5, 2020 File No. 333-239964 Re |
|
| August 5, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 flgt-8k20200804.htm 8-K FOR ATM UPSIZE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other |
|
| August 5, 2020 |
As filed with the Securities and Exchange Commission on August 5, 2020 Registration No. |
|
| August 5, 2020 |
10-Q 1 flgt-10q20200630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| August 5, 2020 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) $44,920,000 Common Stock We have entered into an equity distribution agreement, dated August 30, 2019 with Piper Sandler & Co., or Piper Sandler, as amended on August 4, 2020, or the Equity Distribution Agreement, relating to shares of our common sto |
|
| August 5, 2020 |
Exhibit 1.1 AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT August 4, 2020 Ladies and Gentlemen: Fulgent Genetics, Inc. (the “Company”) and Piper Sandler & Co. (formerly known as Piper Jaffray & Co.) (the “Agent”) are parties to that certain Equity Distribution Agreement dated August 30, 2019 (the “Original Agreement”). All capitalized terms used but not defined in this Amendment No. 1 to the Ori |
|
| August 5, 2020 |
3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com August 5, 2020 VIA EDGAR & OVERNIGHT MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: Fulgent Genetics, Inc. Registration Statement on Form S-3 Filed July 21, 2020 File No. 333-239964 (the “Registration Statement”) La |
|
| August 4, 2020 |
Exhibit 99.1 Fulgent Genetics Reports Record Second Quarter 2020 Financial Results Second Quarter 2020 Results: • Record Revenue of $17.3 million, growing 105% year-over-year • Record Billable tests delivered total 180,513, growing 1003% year-over-year • Gross Margin improved approximately 8 percentage points from Q1 2020; cost per test improved approximately 81% year-over-year • Record GAAP earni |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2020 |
Entry into a Material Definitive Agreement 8-K 1 flgt-8k20200717.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2020 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of |
|
| July 21, 2020 |
Form of Subordinated Indenture Exhibit 4.5 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313( |
|
| July 21, 2020 |
S-3 1 flgt-s3.htm S-3 As filed with the Securities and Exchange Commission on July 20, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation) (I. |
|
| July 21, 2020 |
Exhibit 4.4 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.0 |
|
| June 12, 2020 |
FLGT / Fulgent Genetics, Inc. / Xi Long USA, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2-Exit Filing)* FULGENT GENETICS, INC. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 359664109 (CUSIP Number of Class of Securities) June 8, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| June 2, 2020 |
FLGT / Fulgent Genetics, Inc. / Xi Long USA, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* FULGENT GENETICS, INC. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 359664109 (CUSIP Number of Class of Securities) May 19, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| May 27, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 flgt-8k20200527.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of inco |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 6, 2020 |
Fulgent Genetics, Inc. Up to $30,000,000 Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 Prospectus Supplement (To Prospectus Dated August 23, 2019) Fulgent Genetics, Inc. Up to $30,000,000 Common Stock We previously entered into an equity distribution agreement, dated August 30, 2019 (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”) pursuant to which we may offer a |
|
| May 4, 2020 |
Exhibit 99.1 Fulgent Genetics Reports First Quarter 2020 Financial Results First Quarter 2020 Results: • Revenue totals $7.8 million, growing 44% year over year • Billable tests delivered total 13,163, growing 75% year over year • Gross Margin improves approximately 3 percentage points year over year; cost per test improves approximately 22% year over year • GAAP loss of $2.0 million, or $0.09 per |
|
| May 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 flgt-8k20200504.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incor |
|
| April 17, 2020 |
definitive proxy statement for the 2020 Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| March 13, 2020 |
FLGT / Fulgent Genetics, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| March 13, 2020 |
Description of the registrant’s securities. Exhibit 4.3 DESCRIPTION OF FULGENT GENETICS, INC.’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, Fulgent Genetics, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share, or Common Stock. Unless the context otherwis |
|
| March 10, 2020 |
Exhibit 99.1 Fulgent Genetics Reports Fourth Quarter and Full Year 2019 Financial Results Fourth Quarter 2019 Results: • Revenue totals $8.4 million, growing 48% year over year • Billable tests delivered total 13,977, growing 118% year over year • Gross Margin improves more than 5 percentage points year over year; cost per test improves approximately 40% year over year • GAAP loss of $296,000, or |
|
| March 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2020 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| November 15, 2019 |
424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 PROSPECTUS SUPPLEMENT (To Prospectus dated August 23, 2019) 2,325,000 Shares Common Stock We are offering 2,325,000 shares of our common stock in this offering. Our common stock is listed on The Nasdaq Global Market, or Nasdaq, under the symbol “FLGT.” On November 13, 2019, the last reported sale price for ou |
|
| November 14, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 flgt-8k20191113.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdictio |
|
| November 14, 2019 |
Fulgent Genetics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Fulgent Genetics Announces Pricing of Public Offering of Common Stock TEMPLE CITY, Calif., Nov. 13, 2019 —Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced the pricing of its previously announced underwritten public offering of 2,325,000 shares of its common |
|
| November 14, 2019 |
Fulgent Genetics Announces Proposed Public Offering of Common Stock EX-99.1 4 flgt-ex991184.htm EX-99.1 Exhibit 99.1 Fulgent Genetics Announces Proposed Public Offering of Common Stock TEMPLE CITY, Calif., November 13, 2019 —Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced that it has commenced an underwritten public offering of its com |
|
| November 14, 2019 |
EX-1.1 2 flgt-ex11203.htm EX-1.1 Exhibit 1.1 2,325,000 Shares1 Fulgent Genetics, Inc. Common Stock PURCHASE AGREEMENT November 13, 2019 PIPER JAFFRAY & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Fulgent Genetics, Inc., a Delaware corporation (the “Compa |
|
| November 13, 2019 |
SUBJECT TO COMPLETION, DATED NOVEMBER 13, 2019 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we |
|
| November 8, 2019 |
FLGT / Fulgent Genetics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| November 4, 2019 |
Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2019 Financial Results Third Quarter 2019 Results: • Record billable tests of 20,697, growing 272% year over year • Record revenue of $10.3 million, growing 84% year over year • Gross Margin improves 8.9 percentage points year over year and 5.4 percentage points sequentially; cost per test improves 60% year over year and 15% sequentially • Posts |
|
| November 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission F |
|
| October 24, 2019 |
FLGT / Fulgent Genetics, Inc. / Hsieh Ming - SC 13D/A Activist Investment SC 13D/A 1 none-sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Ming Hsieh c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue, Suite 205 Temple |
|
| September 13, 2019 |
FLGT / Fulgent Genetics, Inc. / Gao Hanlin - SC 13D/A Activist Investment SC 13D/A 1 none-sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Fulgent Genetics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 359664109 (CUSIP Number) Han Lin Gao c/o Fulgent Genetics, Inc. 4978 Santa Anita Avenue, Suite 205 Temple |
|
| August 30, 2019 |
PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) Common Stock 424B5 1 flgt-424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-233227 PROSPECTUS SUPPLEMENT (to Prospectus dated August 23, 2019) $22,500,000 Common Stock We have entered into an equity distribution agreement, dated August 30, 2019, or the Equity Distribution Agreement, with Piper Jaffray & Co., or Piper Jaffray, relating to shares of our common stock, par value $0.0001 per sha |
|
| August 30, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2019 Fulgent Genetics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission |
|
| August 30, 2019 |
Exhibit 1.1 FULGENT GENETICS, INC. EQUITY DISTRIBUTION AGREEMENT August 30, 2019 PIPER JAFFRAY & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Fulgent Genetics, Inc., a company organized under the laws of the State of Delaware (the “Company”), proposes to issue and sell from time to time throu |
|
| August 21, 2019 |
FLGT / Fulgent Genetics, Inc. CORRESP - - CORRESP 1 filename1.htm FULGENT GENETICS, iNC. 4978 Santa Anita Avenue, Suite 205 Temple City, CA 91780 August 21, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jonathan Burr RE:Fulgent Genetics, Inc. Registration Statement on Form S-3 Filed August 12, 2019 File No. 333-233227 Request for Acceler |
|
| August 12, 2019 |
Form of Subordinated Indenture flgt-ex45_18.htm Exhibit 4.5 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313 |
|
| August 12, 2019 |
EX-4.4 2 flgt-ex4419.htm EX-4.4 Exhibit 4.4 FULGENT GENETICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.0 |
|
| August 12, 2019 |
FLGT / Fulgent Genetics, Inc. S-3 - - S-3 S-3 1 flgt-s3.htm S-3 As filed with the Securities and Exchange Commission on August 12, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation) (I |
|
| August 12, 2019 |
FLGT / Fulgent Genetics, Inc. 10-Q - Quarterly Report - 10-Q 10-Q 1 flgt-10q20190630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fi |
|
| August 12, 2019 |
Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is not material. Double asterisks denote omissions. Supplemental Agreement to Cooperation Agreement Party A: Shenzhen Fujin Gene Technology Co., Ltd. Legal Address: Room 201, Building A, No. 1, Qianwan 1st Road, Qianhai Shenzhen-Hong Kong Cooperation Zone, Shenzhen (occupied in Shenzhen Qianhai Commerce Secre |
|
| August 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File |
|
| August 5, 2019 |
Exhibit 99.1 Fulgent Genetics Reports Second Quarter 2019 Financial Results Second Quarter 2019 Results: • Record billable tests of 16,369, growing 187% year over year • Record revenue of $8.4 million, growing 56% year over year • Gross Margin improves more than 12 percentage points sequentially; cost per test improves by 44% sequentially • Posts profit; GAAP income of $331,000, or $0.02 per share |
|
| August 5, 2019 |
8-K 1 flgt-8k20190801.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of in |
|
| August 5, 2019 |
Fulgent Genetics Names Linda Marsh to Board of Directors Exhibit 99.1 Fulgent Genetics Names Linda Marsh to Board of Directors TEMPLE CITY, California –August 5, 2019 – Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to its board of directors, effective August 1. “We’re honored to welcome Ms. Marsh to our Board of |
|
| June 3, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 10, 2019 |
FLGT / Fulgent Genetics, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| May 7, 2019 |
Exhibit 99.1 Fulgent Genetics Reports First Quarter 2019 Financial Results First Quarter 2019 Results: • Revenue totals $5.4 million, growing 15% year over year • Billable tests delivered total 7,530, growing 63% year over year • GAAP loss of $1.9 million, or $0.10 per share • Non-GAAP loss of $1.0 million, or $0.06 per share • Adjusted EBITDA loss of $712,000 • Cash flow from operations of positi |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 17, 2019 |
definitive proxy statement for the 2019 Annual Meeting of Stockholders DEF 14A 1 flgt-def14a20190530.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| March 22, 2019 |
FLGT / Fulgent Genetics, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37894 FULGENT GENETIC |
|
| March 22, 2019 |
EX-10.24 3 flgt-ex1024270.htm EX-10.24 Exhibit 10.24 AMENDED AND COMPLETELY RESTATED STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE-GROSS RECITALS: A.Pursuant to that certain Standard Industrial/Commercial Multi-Tenant Lease - Gross dated May 31, 2017, as amended by (i) that certain First Amendment to Standard Industrial/Commercial Multi-Tenant Lease - Gross dated August 17, 2017, and (ii) that |
|
| March 22, 2019 |
Exhibit 10.23 COMMERCIAL LEASE This Lease is made and entered into between E & E Plaza, LLC, herein called Lessor, and Fulgent Therapeutics, LLC. herein called Lessee. Lessee hereby offers to lease from Lessor the premises situated in the City of Temple City County of Los Angeles, State of California, described as 4978 Santa Anita Ave. #101,#102,#103,#104,#105,#201,#202,#203,#204&,#205, Temple Cit |
|
| March 22, 2019 |
Subsidiaries of the registrant. Exhibit 21.1 SUBSIDIARIES OF FULGENT GENETICS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Fulgent Therapeutics LLC California Fulgent Investment Development Limited Hong Kong Shenzhen Mingrui Consulting Co., Ltd. China Fulgent Genetics Canada Inc. Canada Shenzhen Fujin Gene Technology Co., Ltd. China |
|
| February 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 flgt-8k20190228.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of |
|
| February 28, 2019 |
EX-99.1 2 flgt-ex9916.htm EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter 2018 Results: • Revenue totals $5.7 million, growing 33% year over year • Billable tests delivered total 6,408, growing 52% year over year • GAAP loss of $935,000, or $0.05 per share • Non-GAAP loss of $193,000, or $0.01 per share • Adjusted EBITDA of $50,000 F |
|
| November 9, 2018 |
FLGT / Fulgent Genetics, Inc. 10-Q (Quarterly Report) 10-Q 1 flgt-10q20180930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi |
|
| November 6, 2018 |
Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2018 Financial Results Third Quarter 2018 Results: • Revenue totals $5.6 million, growing 25% year over year and 4% sequentially • Billable tests delivered total 5,569, growing 37% year over year • GAAP gross margin improves 70 basis points sequentially • Non-GAAP gross margin remains flat sequentially • GAAP loss of $595,000, or $0.03 per share |
|
| November 6, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 13, 2018 |
FLGT / Fulgent Genetics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37894 FULGENT GENETICS, INC. |
|
| August 6, 2018 |
Exhibit 99.1 Fulgent Genetics Reports Second Quarter 2018 Financial Results Second Quarter 2018 Results: • Revenue totals $5.4 million, growing 16% year over year and 16% sequentially • Billable tests delivered total 5,700, growing 47% year over year and 23% sequentially • GAAP and non-GAAP gross margins each improve over 12 points sequentially • GAAP loss of $1.0 million, or $0.06 per share • Non |
|
| August 6, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 flgt-8k20180806.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2018 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of in |
|
| May 21, 2018 |
Fulgent Genetics, Inc. Amended and Restated 2016 Omnibus Incentive Plan Exhibit 10.1 FULGENT GENETICS, INC. 2016 OMNIBUS INCENTIVE PLAN (as amended and restated effective May 18, 2018) 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. 2. Definitions. The following definitions shall apply |
|
| May 21, 2018 |
8-K 1 flgt-8k20180518.htm 8-K FOR ANNUAL MEETING OF STOCKHOLDERS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2018 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 ( |
|
| May 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 flgt-10q20180331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F |
|
| May 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 flgt-8k20180507.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2018 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incor |
|
| May 7, 2018 |
Exhibit 99.1 Fulgent Genetics Reports First Quarter 2018 Financial Results First Quarter 2018 Results: • Revenue of $4.7 million, up 9% sequentially • Billable tests delivered grew 10% sequentially to 4,621 • GAAP loss of $1.9 million, or $0.11 per share • Non-GAAP loss of $1.2 million, or $0.06 per share • Adjusted EBITDA loss of $1.1 million TEMPLE CITY, CA, May 7, 2018 —Fulgent Genetics (NASDAQ |
|
| April 13, 2018 |
FLGT / Fulgent Genetics, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Defin |
|
| March 20, 2018 |
EX-10.23 3 flgt-ex1023164.htm EX-10.23 Exhibit 10.23 COMMERCIAL LEASE This Lease is made and entered into between E & E Plaza, LLC, herein called Lessor, and Fulgent Therapeutics, LLC. herein called Lessee. Lessee hereby offers to lease from Lessor the premises situated in the City of Temple City County of Los Angeles, State of California, described as 4978 Santa Anita Ave. #101,#102,#103,#104,#10 |
|
| March 20, 2018 |
EX-10.20 2 flgt-ex102063.htm EX-10.20 Exhibit 10.20 FULGENT GENETICS, INC. DIRECTOR COMPENSATION PROGRAM This Director Compensation Program (this “Program”) sets forth the compensation payable to directors of Fulgent Genetics, Inc., a Delaware corporation (the “Company”), as consideration for their service as directors of the Company. This Program does not constitute a legally binding contract or |
|
| March 20, 2018 |
FLGT / Fulgent Genetics, Inc. 10-K (Annual Report) 10-K 1 flgt-10k20171231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| February 28, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2018 FULGENT GENETICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37894 81-2621304 (State or other jurisdiction of incorporation) (Commission Fi |
